Pharma's Almanac

What Pharma's Almanac does

Pharma's Almanac is a B2B digital publishing platform serving the life-sciences industry, operated as part of the That's Nice LLC family of companies alongside the Nice Insight market research division. The platform publishes editorial content spanning 30+ life-sciences verticals including APIs, biologics, advanced therapies, mRNA, manufacturing, supply chain, clinical trials, technologies, and financing, with contributions drawn from over 1,700 companies and 2,000+ subject-matter experts. Content formats include articles, expert interviews, roundtables, videos, themed content series (the 'Road To' franchise), and press releases, distributed through a gated digital platform that requires user registration for premium access.

The company's product surface combines a core content hub, the Nice Insight research division that tracks 500+ global CDMOs across 10 therapeutic modalities and publishes CDMO pricing benchmarks and competitor analysis, and flagship annual reports including State of the Industry 2026. The underlying technology is a standard digital publishing and content management platform with no disclosed proprietary APIs, SDKs, or AI/ML capabilities. Distribution relies on the website, email newsletters, LinkedIn, webinars, and syndicated press releases.

Pharma's Almanac operates a hybrid revenue model combining subscription and membership fees for access to gated premium content and research reports with sponsored content and advertising from life-sciences advertisers. Pricing is not publicly disclosed. The platform serves CDMO/CRO executives, R&D leaders, and life-sciences professionals globally, with headquarters in New York and international reach supported by parent-company offices in London, Manchester, Frankfurt, and Hangzhou. Editor-in-Chief David Alvaro, Ph.D., provides editorial leadership.

Name

Pharma's Almanac

Legal name

Pharma's Almanac

Website

https://pharmasalmanac.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Pharma's Almanac is a B2B digital publishing platform serving life-sciences professionals with editorial content, expert interviews, and the Nice Insight CDMO market research division, operated under parent company That's Nice LLC.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Subscription/Membership: Premium membership providing access to members-only articles, Nice Insight Trends & Opinions reports, roundtable insights, and expert interviews. The platform operates a subscription model where users register and subscribe to access exclusive content.
2. Sponsored Content and Advertising: The platform publishes sponsored content and features third-party advertisements. This includes sponsored programs, advertising through email communications, and featured sponsored articles and reports.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Pharma's Almanac is a digital publishing platform dedicated to thought leadership in the pharmaceutical outsourcing space. It publishes articles, expert interviews, roundtables, press releases, and videos spanning APIs, biologics, advanced therapies, mRNA, manufacturing, supply chain, clinical trials, and financing. Through its Nice Insight market research division, the platform also produces proprietary CDMO pricing benchmarks, competitor analysis, and annual industry reports such as State of the Industry.

Product overview

Pharma's Almanac is a unified content publishing platform for life sciences thought leadership, operated by That's Nice LLC. The platform is structured as a core content hub (Pharma's Almanac) supplemented by the Nice Insight market research division, which provides proprietary industry reports and CDMO benchmarking data. Content spans articles, expert interviews, roundtables, videos, and research reports covering APIs, biologics, advanced therapies, manufacturing, supply chain, clinical trials, and financing. The platform aggregates contributions from over 1,700 companies and 2,000+ subject-matter experts across 30+ life-science verticals.

Differentiator

Problem solved

Functional benefit

Brands

• Nice Insight: Market research division providing CDMO pricing benchmarks, industry reports, and market analysis for the life sciences sector.

Products and services

• Pharma's Almanac Platform Premier digital publishing platform delivering thought leadership content, expert commentary, and curated roundtables for life sciences professionals covering APIs, biologics, advanced therapies, mRNA, manufacturing, supply chain, clinical trials, and financing topics.
• Nice Insight Market Research Market research division providing CDMO pricing benchmarks, competitor analysis, and market intelligence across 10 therapeutic modalities including mammalian cell culture, ADCs, sterile fill finish, APIs, oral solid dose, microbial fermentation, gene therapy, and cell therapy. Tracks over 500 global CDMOs.
• State of the Industry 2026 Report Annual industry report providing deep analysis of the global CDMO landscape, including pricing dynamics, manufacturing trends, and therapeutic pipeline analysis for life sciences outsourcing decision-makers.
• Content Hub (Articles, Interviews, Roundtables) Collection of articles, expert interviews, roundtables, press releases, and videos covering drug discovery, manufacturing, supply chain, clinical trials, technologies, and financing topics for life sciences professionals.
• Road To Series Themed content series covering geographic and topic-specific pharma industry landscapes, including The Road To Experience, The Road To Ireland, The Road To 2021, The Road To 50 States, The Road To BIO, and The Road To 30.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Nice InsightcoreTechnology or IntegrationNice Insight is the market research division of That's Nice LLC, the parent company of Pharma's Almanac. Nice Insight provides proprietary market research, CDMO pricing benchmarks, and competitive analysis for the pharmaceutical outsourcing industry. The research division tracks over 500 global CDMOs and publishes industry reports including the State of the Industry 2026 focusing on the CDMO landscape.

Scale indicators4 records

Recent moves2 records

Expansion highlights5 records

Direct peers

• BioSpace: BioSpace is a long-established life-sciences industry news, jobs, and community platform that competes for the same biotech/pharma professional readership. Both operate gated content models and monetize through sponsorships, advertising, and talent solutions targeting life-sciences professionals.
• Endpoints News: Endpoints News is a B2B news publication covering the biopharma industry with a similar subscription-led, content-driven GTM motion. It targets many of the same life-sciences professionals Pharma's Almanac serves and competes directly for sponsored content, executive interviews, and reader attention.
• Outsourced Pharma: Outsourced Pharma specializes in pharmaceutical outsourcing and contract services content, directly overlapping Pharma's Almanac's core coverage of CDMO/CRO market intelligence, manufacturing, and supply chain. Both serve CDMO executives and sponsor relationships in the same outsourcing decision-maker audience.
• Contract Pharma: Contract Pharma publishes content and operates media properties focused on contract development, manufacturing, and services for pharmaceuticals. It shares Pharma's Almanac's target buyer (CDMO executives) and sponsored content model, with overlapping coverage of API manufacturing, biologics, and sterile fill finish.
• PharmaVoice: PharmaVoice publishes executive interviews, thought leadership, and industry insights targeting pharmaceutical and biotech leaders—a content-led B2B model very similar to Pharma's Almanac. Both monetize through sponsored features, executive access, and a deep editorial focus on life-sciences decision-makers.

Broad incumbents

• BioPharm International (Informa): BioPharm International is an Informa-owned B2B publication covering biopharmaceutical development, manufacturing, and regulatory topics. It competes with Pharma's Almanac's biologics and manufacturing verticals for the same R&D and manufacturing leaders' attention and overlaps in CDMO/contract services coverage.
• Citeline / Pharma Intelligence (Informa): Citeline (Informa's Pharma Intelligence) provides proprietary clinical trial intelligence, drug pipeline data, and market research to pharma and biotech subscribers. It overlaps with Nice Insight's market-research franchise, particularly for pipeline and CDMO intelligence customers willing to pay for premium data subscriptions.
• Fierce Pharma / Fierce Biotech: Fierce Pharma (part of Questex) is an established, larger pharma industry news publication covering drug development, manufacturing, and commercialization. It serves a broader life-sciences audience than Pharma's Almanac's CDMO-outsourcing niche, but competes for the same executives' attention and sponsorships.
• Pharmaceutical Technology (Informa): Pharmaceutical Technology is an Informa publication covering drug development, manufacturing technologies, and pharmaceutical processing. It serves an overlapping audience of manufacturing, formulation, and technology buyers, with similar sponsored content and B2B advertising revenue models.
• Pharmaceutical Executive (MJH Life Sciences): Pharmaceutical Executive is a long-established B2B publication serving pharma executives with editorial content and sponsored features. It sits in the same thought-leadership C-suite category and competes with Pharma's Almanac for executive readership and corporate sponsorship budgets across the same accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmasalmanac
• Xx.com/pharmasalmanac

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma's Almanac